Detection of Thrombosis Using Soluble C-Type Lectin-like Receptor-2 with D-Dimer Level and Platelet Count.

Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101606588 Publication Model: Electronic Cited Medium: Print ISSN: 2077-0383 (Print) Linking ISSN: 20770383 NLM ISO Abbreviation: J Clin Med Subsets: PubMed not MEDLINE

Original Publication: Basel, Switzerland : MDPI AG, [2012]-

Introduction : Soluble C-type lectin-like receptor -2 (sCLEC-2) has been recognized as a marker of platelet activation, and attention has been drawn to formulas combining sCLEC-2 levels with platelet count and D-dimer levels. Methods : In this study, sCLEC-2 levels, as well as sCLEC-2/platelet count (sCLEC-2/PLT), sCLEC-2 × D-dimer (sCLEC-2xDD), and sCLEc-2xDD/PLT formulas were used to detect thrombotic diseases, including microvascular thrombosis (MVT), arterial thromboembolism (ATE), and venous thromboembolism (VTE), with the aim of evaluating the ability of the three parameters combined in these formulas to diagnose thrombotic diseases. Results : The plasma sCLEC-2 levels were significantly higher in patients with infectious or thrombotic diseases than in those with neither thrombosis nor infection; however, there was no significant difference among patients with infection, ATE, VTE, and MVT; the correlations among sCLEC-2, platelet count, and D-dimer level were poor. The sCLEC-2/PLT ratio was the highest in patients with MVT, and the sCLEC-2 × D-dimer value was higher in patients with MVT and VTE than in those with neither thrombosis nor infection. Although receiver operating characteristic (ROC) analysis shows the differential diagnosis of thrombotic diseases from non-thrombosis without infection, the sCLEC-2 × D-dimer/platelet count was useful for differential diagnosis among MVT and infection or non-thrombotic diseases. Conclusions : sCLEC-2 is useful for the diagnosis of thrombosis, and the formulas of sCLEC-2 with platelet count or D-dimer are useful for the diagnosis of thrombosis using ROC analyses for the thrombosis group vs. the non-thrombosis group without infection.

Int J Hematol. 2024 May;119(5):495-504. (PMID: 38421488)
Thromb Res. 2024 Mar;235:164-174. (PMID: 38350183)
J Thromb Haemost. 2022 Apr;20(4):975-988. (PMID: 35038779)
J Thromb Haemost. 2022 Sep;20(9):2159-2160. (PMID: 35968794)
Bibl Haematol. 1983;(49):265-75. (PMID: 6667250)
N Engl J Med. 2014 Aug 14;371(7):654-66. (PMID: 25119611)
Cancers (Basel). 2023 Nov 22;15(23):. (PMID: 38067218)
Thromb Res. 2019 Jun;178:54-58. (PMID: 30978634)
Eur Heart J. 2024 Aug 9;45(30):2735-2747. (PMID: 38941344)
Drugs. 2021 Jun;81(8):935-943. (PMID: 33970459)
Clin Appl Thromb Hemost. 2024 Jan-Dec;30:10760296241232858. (PMID: 38403943)
Eur Neurol. 2021;84(1):38-42. (PMID: 33477158)
Blood. 2019 Nov 28;134(22):1912-1918. (PMID: 31778548)
J Clin Med. 2022 Feb 14;11(4):. (PMID: 35207258)
Thromb Haemost. 2018 Nov;118(11):1856-1866. (PMID: 30312978)
Stroke. 2024 Feb;55(2):311-323. (PMID: 38252756)
Semin Thromb Hemost. 2024 Apr;50(3):360-383. (PMID: 36921613)
Platelets. 2015;26(8):711-9. (PMID: 25856065)
Semin Thromb Hemost. 2018 Mar;44(2):126-134. (PMID: 28992650)
Stroke. 2019 Jan;50(1):45-52. (PMID: 30580704)
Int J Hematol. 2019 Sep;110(3):285-294. (PMID: 31165998)
Hamostaseologie. 2024 Jun;44(3):206-217. (PMID: 38467144)
Blood. 2018 Sep 13;132(11):1167-1179. (PMID: 29853539)
Blood. 2023 Jun 1;141(22):2685-2697. (PMID: 36787503)
Thromb Haemost. 2001 Nov;86(5):1327-30. (PMID: 11816725)
JAMA. 2018 Oct 16;320(15):1583-1594. (PMID: 30326130)
Br J Haematol. 2024 Apr;204(4):1176-1177. (PMID: 38263610)
Int J Hematol. 2024 Mar;119(3):240-247. (PMID: 36867357)
Int J Mol Sci. 2023 Apr 28;24(9):. (PMID: 37175680)
Adv Clin Chem. 2023;114:151-223. (PMID: 37268332)
Blood. 2021 Mar 11;137(10):1310-1317. (PMID: 33512445)
Semin Thromb Hemost. 2017 Apr;43(3):311-319. (PMID: 28264200)
Blood Rev. 2021 Nov;50:100864. (PMID: 34217531)
Chest. 2024 Aug;166(2):388-404. (PMID: 38458430)
J Thromb Haemost. 2017 Feb;15(2):219-229. (PMID: 27960039)
Front Mol Biosci. 2024 Mar 13;11:1287553. (PMID: 38545417)
Expert Rev Hematol. 2024 Jan-Mar;17(1-3):55-66. (PMID: 38369947)
Haematologica. 2024 Apr 01;109(4):1035-1045. (PMID: 37881856)
Diagnostics (Basel). 2023 Jul 06;13(13):. (PMID: 37443690)
J Thromb Haemost. 2022 Feb;20(2):434-448. (PMID: 34710269)
BMJ. 2020 Feb 13;368:l6983. (PMID: 32054610)
Thromb Haemost. 2024 Apr;124(4):297-306. (PMID: 37591289)
Heart. 2021 Feb;107(3):237-244. (PMID: 32788198)
J Clin Med. 2021 Jun 28;10(13):. (PMID: 34203210)
Stroke. 2019 Apr;50(4):873-879. (PMID: 30852963)
Arterioscler Thromb Vasc Biol. 2021 Nov;41(11):2681-2692. (PMID: 34496636)
Platelets. 2022 Aug 18;33(6):935-944. (PMID: 35073814)
J Clin Med. 2023 Jan 30;12(3):. (PMID: 36769725)
BMC Cancer. 2017 Aug 30;17(1):591. (PMID: 28854911)
Br J Haematol. 2023 Jun;201(5):851-856. (PMID: 36883298)
Postepy Hig Med Dosw (Online). 2016 Apr 13;70:305-12. (PMID: 27117106)
Blood Rev. 2023 Sep;61:101112. (PMID: 37414719)
J Clin Med. 2024 Apr 03;13(7):. (PMID: 38610867)
Platelets. 2019;30(4):530-534. (PMID: 30365337)
Circulation. 2023 Jun 20;147(25):1933-1944. (PMID: 37335828)
Int J Mol Sci. 2024 Feb 23;25(5):. (PMID: 38473840)
J Thromb Haemost. 2024 Mar;22(3):604-608. (PMID: 38135252)
Front Med. 2020 Feb;14(1):81-90. (PMID: 31280468)
Blood. 2024 Feb 8;143(6):535-547. (PMID: 37992231)
Medicine (Baltimore). 2024 Jan 19;103(3):e36936. (PMID: 38241567)
JAMA Neurol. 2020 Nov 07;:. (PMID: 33159526)
J Clin Med. 2021 Jul 30;10(15):. (PMID: 34362190)
Int J Lab Hematol. 2022 Sep;44 Suppl 1:101-113. (PMID: 36074708)

21FC1008 the Ministry of Health, Labor and Welfare of Japan; unknown PHC Holding Corporation

Keywords: D-dimer; arterial thrombosis; micro thrombosis; platelet count; sCLEC-2; venous thrombosis

Date Created: 20241016 Latest Revision: 20241019

20241019

PMC11477887

10.3390/jcm13195980

39408040